Previous 10 | Next 10 |
NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor ...
NEW YORK, July 01, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor ...
NEW YORK, July 01, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor ...
Checkpoint Therapeutics (NASDAQ: CKPT ): Q1 GAAP EPS of -$0.18 beats by $0.09 . More news on: Checkpoint Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor c...
Preliminary data from a Phase 1 clinical trial assessing Checkpoint Therapeutics' ( CKPT +5% ) lead immuno-oncology candidate cosibelimab (formerly CK-301) showed a treatment effect. More news on: Checkpoint Therapeutics, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, He...
>40% objective response rates observed in first-line non-small cell lung cancer and cutaneous squamous cell carcinoma Well-tolerated safety profile Enrollment ongoing in expansion cohorts intended to support potential BLA submissions NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -...
Mustang Bio, Inc. ( MBIO ) soared last Thursday after the very successful results of its gene therapy, MB-107, for X-linked Severe Combined Immunodeficiency, or X-SCID, were published in the New England Journal of Medicine. The therapy, licensed from the St. Jude Children's Research Hospital, ...
Gainers : Mustang Bio (NASDAQ: MBIO ) +117% . Checkpoint Therapeutics (NASDAQ: CKPT ) +19% . Amyris (NASDAQ: AMRS ) +18% . Uxin (NASDAQ: UXIN ) +17% . Viomi Technology (NASDAQ: VIOT ) +16% . Fortress Biotech (NASDAQ: FBIO ) +15% . Broadwind Energy (NASDAQ: BWEN ) +13% . Libbey (NYSE...
NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor ...
News, Short Squeeze, Breakout and More Instantly...
Checkpoint Therapeutics Inc. Company Name:
CKPT Stock Symbol:
NASDAQ Market:
Checkpoint Therapeutics Inc. Website:
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Check...
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoin...
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional in...